Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est

Benzinga Newsdesk www.benzinga.com Negative 52.8%

Neg 52.8% Neu 0% Pos 0%

Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion vs $6.745 billion estimate.